Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CBP-1019 |
| Trade Name | |
| Synonyms | CBP 1019|CBP1019 |
| Drug Descriptions |
CBP-1019 is a bispecific ligand-drug conjugate that targets FOLR1 (FRalpha) and TRPV6 and contains exatecan (DX-8951), which potentially inhibits tumor growth (Ann Oncol (2024) 35 (Suppl_2): S512-S513). |
| DrugClasses | FOLR1-targeted Therapy 24 |
| CAS Registry Number | NA |
| NCIT ID | C200554 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin | Bevacizumab CBP-1019 Fluorouracil Leucovorin Oxaliplatin | 0 | 1 |
| CBP-1019 | CBP-1019 | 0 | 1 |
| CBP-1019 + Enzalutamide | CBP-1019 Enzalutamide | 0 | 1 |
| CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin | CBP-1019 Fluorouracil Leucovorin Oxaliplatin | 0 | 1 |
| CBP-1019 + Pembrolizumab | CBP-1019 Pembrolizumab | 0 | 1 |